68819-84-1

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-BROMOBENZYLCARBAMATE is used as an organic synthetic intermediate for the production of a variety of drugs. Its unique structural composition allows it to serve as a key component in the synthesis of pharmaceutical compounds, contributing to the development of new medications and therapies.
Used in Organic Synthesis:
In the field of organic synthesis, TERT-BUTYL 4-BROMOBENZYLCARBAMATE is used as a building block for the creation of more complex molecules. Its versatility in chemical reactions makes it a valuable asset in the synthesis of a wide range of organic compounds, including those with potential applications in various industries such as agriculture, materials science, and chemical research.

InChI:InChI=1S/C12H16BrNO2/c1-12(2,3)16-11(15)14-8-9-4-6-10(13)7-5-9/h4-7H,8H2,1-3H3,(H,14,15)

Upstream product

• 66389-77-3 methyl tert-butyl iminodicarboxylate potassium salt 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3959-07-7 4-Bromobenzylamine 
• 1228692-99-6 C₂₃H₂₁BrF₁₇NO₃ 
• 107047-10-9 p-bromobenzylazide 
• 4248-19-5 tert-butyl carbazate 
• 1122-91-4 4-bromo-benzaldehyde 
• 1145-80-8 N-(benzyloxycarbonyl)-L-serine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 153171-22-3 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione 
• 26177-44-6 4-bromobenzylamine hydrochloride 

Downstream Products

• 312760-15-9 2-benzenesulfonylamino-3-({5-[4-(tert-butoxycarbonylamino-methyl)-phenyl]-thiophene-2-carbonyl}-amino)-propionic acid tert-butyl ester 
• 625116-32-7 [4-(1-ethoxy-vinyl)-benzyl]-carbamic acid tert-butyl ester 
• 935528-04-4 (4-trimethylsilylprop-1-ynylbenzyl)carbamic acid tert-butyl ester 
• 214961-71-4 2-amino-4'-tert-butoxycarbonylaminomethyl-5-chlorobenzophenone 
• 928648-78-6 N-(tert-butoxycarbonyl)-4-cyclohexylethynyl-benzylamine 
• 880158-62-3 tert-butyl N-[4-(furan-3-yl)benzyl]-carbamate 
• 880156-91-2 tert-Butyl N-(3'-benzyloxycarbonylbiphenyl-4-ylmethyl)-carbamate 
• 880156-86-5 tert-butyl N-(3'-benzyloxybiphenyl-4-ylmethyl)carbamate 
• 1443787-05-0 (±)-tert-butyl (4-(1-oxo-2,3-dihydro-1H-inden-2-yl)benzyl)carbamate 
• 1450916-70-7 C₂₉H₂₄F₆N₂S₂ 
• 1616590-16-9 (4,4-dimethyl-3,4-dihydrocarbostyril)-6-carboxylic acid (E)-4-[2-(hydroxycarbamoyl)vinyl]benzylamide 
• 1616590-38-5 (E)-3-[4-(4,4-dimethyl-3,4-dihydrocarbostyril-6-carbonyl)aminomethylphenyl]acrylic acid ethyl ester 
• 1448191-54-5 tert‐butyl (2S,4R)‐4‐hydroxy‐2‐({[4‐(4‐methyl‐1,3‐thiazol‐5‐yl)phenyl]methyl}carbamoyl)pyrrolidine‐1‐carboxylate 

Relevant academic research and scientific papers

Synthesis and structure activity relationship of the first class of LXR inverse agonists

Liver X Receptors (LXRs) are members of the nuclear receptor family, and they play significant role in lipid and cholesterol metabolism. Moreover, they are key regulators of several inflammatory pathways. Pharmacological modulation of LXRs holds great pot

Small molecule compound based on EZH2 protein degradation, and application thereof

The invention discloses a series of small molecule compounds capable of selectively degrading EZH2 protein, and application thereof. The compounds can be prepared into proper pharmaceutical dosage forms for EZH2-mediated related tumor treatment.

Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma

Traditional EZH2 inhibitors are developed to suppress the enzymatic methylation activity, and they may have therapeutic limitations due to the nonenzymatic functions of EZH2 in cancer development. Here, we report proteolysis-target chimera (PROTAC)-based EZH2 degraders to target the whole EZH2 in lymphoma. Two series of EZH2 degraders were designed and synthesized to hijack E3 ligase systems containing either von Hippel-Lindau (VHL) or cereblon (CRBN), and some VHL-based compounds were able to mediate EZH2 degradation. Two best degraders, YM181 and YM281, induced robust cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphomas, outperforming a clinically used EZH2 inhibitor EPZ6438 (tazemetostat) that was only effective against DLBCL. The EZH2 degraders displayed promising antitumor activities in lymphoma xenografts and patient-derived primary lymphoma cells. Our study demonstrates that EZH2 degraders have better therapeutic activity than EZH2 inhibitors, which may provide a potential anticancer strategy to treat lymphoma.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF

The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.

PROCESS FOR THE PREPARATION OF PANOBINOSTAT

The present invention relates to a new process for the preparation of Panobinostat and intermediates thereof.

Compound targeting to I-type PRMT and preparation method and application of compound

The invention relates to the technical field of chemical drugs, in particular to a compound targeting to I-type PRMT, and a preparation method and application thereof. The compound A and a pharmaceutically acceptable salt thereof belong to covalent inhibi

ANDROGEN RECEPTOR PROTEIN DEGRADERS

The present disclosure provides compounds represented by Formula (I): A—L—B (I), and the salts or solvates thereof, wherein A, L, and B are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer.

QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS

The present disclosure provides certain quinazoline compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Atorvastatin Derived HMG-CoA Reductase Degradation Inducing Compound

The present invention relates to a HMG-CoA reductase degradation-inducing compound and, more specifically, to a bifunctional compound in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked as HMG-CoA reductase binding moiety, to a production method thereof, to a HMG-CoA reductase degradation method using the same, and to a pharmaceutical composition for preventing or treating HMG-CoA reductase-related diseases, comprising the same.